Peginterferon and ribavirin treatment for hepatitis C virus infection |
| |
Authors: | Tsubota Akihito Fujise Kiyotaka Namiki Yoshihisa Tada Norio |
| |
Affiliation: | Akihito Tsubota,Kiyotaka Fujise,Yoshihisa Namiki,Norio Tada,Institute of Clinical Medicine and Research,Jikei University School of Medicine,163-1 Kashiwa-shita,Kashiwa,Chiba 277-8567,Japan |
| |
Abstract: | Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients. |
| |
Keywords: | Pegylated interferon α Ribavirin Chronic hepatitis C virus infection Difficult-to-treat patient Individualized treatment Response-guided therapy Specifically targeted antiviral therapy for hepatitis C virus |
本文献已被 CNKI 维普 PubMed 等数据库收录! |
|